SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia.

Vevoctadekin is under clinical development by Simcha Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.

Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic ...

Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Expec ...

Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...

In a significant advancement for cancer research, a team of scientists from Max Planck Institute for Biology Tübingen, ...

Researchers sought to determine if HRQoL measures differ with gilteritinib compared with placebo in patients with AML.

A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug ...

Eunice S. Wang, MD, discusses a retrospective study of 105 patients diagnosed with secondary acute myeloid leukemia.

A special blood drive was held Monday afternoon to honor a Cranston High School East teacher battling leukemia.

LONDON, UK / ACCESSWIRE / January 8, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has raised £340,000 through the issue of 100,000 new ordinary shares ('Placing ...

Interesting trends were observed in the subgroup analyses of the phase 3 uproleselan study in relapsed or refractory acute ...